Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
11.10 x 1 14.90 x 2
Pre-market by (Cboe BZX)
13.21 -0.03 (-0.23%) 04/22/25 [NASDAQ]
11.10 x 1 14.90 x 2
Pre-market 13.21 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
12.94
Day High
13.63
Open 13.49
Previous Close 13.24 13.24
Volume 502,700 502,700
Avg Vol 1,220,885 1,220,885
Stochastic %K 49.31% 49.31%
Weighted Alpha -0.75 -0.75
5-Day Change -0.71 (-5.10%) -0.71 (-5.10%)
52-Week Range 8.24 - 18.38 8.24 - 18.38
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 858,958
  • Shares Outstanding, K 64,876
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,810 K
  • EBIT $ -192 M
  • EBITDA $ -192 M
  • 60-Month Beta -0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.47

Options Overview Details

View History
  • Implied Volatility 87.87% ( -14.24%)
  • Historical Volatility 88.82%
  • IV Percentile 39%
  • IV Rank 18.61%
  • IV High 403.07% on 02/28/25
  • IV Low 15.79% on 06/21/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 38
  • Volume Avg (30-Day) 661
  • Put/Call OI Ratio 3.02
  • Today's Open Interest 2,971
  • Open Int (30-Day) 14,113

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.02
  • Number of Estimates 2
  • High Estimate -0.90
  • Low Estimate -1.14
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -45.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.44 +26.53%
on 04/09/25
Period Open: 16.87
17.35 -23.86%
on 03/24/25
-3.66 (-21.70%)
since 03/21/25
3-Month
8.24 +60.30%
on 02/25/25
Period Open: 10.19
18.38 -28.13%
on 03/19/25
+3.02 (+29.64%)
since 01/22/25
52-Week
8.24 +60.30%
on 02/25/25
Period Open: 11.14
18.38 -28.13%
on 03/19/25
+2.07 (+18.58%)
since 04/22/24

Most Recent Stories

More News
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

SANA : 1.7300 (+8.81%)
MLYS : 13.21 (-0.23%)
AEON : 0.4050 (+1.25%)
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

MLYS : 13.21 (-0.23%)
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.4548 (-0.74%)
CSCI : 3.04 (-0.49%)
MLYS : 13.21 (-0.23%)
SWTX : 40.50 (+9.28%)
MGX : 1.7000 (+1.80%)
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

MLYS : 13.21 (-0.23%)
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

MLYS : 13.21 (-0.23%)

Business Summary

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 14.27
2nd Resistance Point 13.95
1st Resistance Point 13.58
Last Price 13.21
1st Support Level 12.89
2nd Support Level 12.57
3rd Support Level 12.20

See More

52-Week High 18.38
Fibonacci 61.8% 14.51
Fibonacci 50% 13.31
Last Price 13.21
Fibonacci 38.2% 12.11
52-Week Low 8.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro